PRESENTER

DAY

TITLE

Agenda

June 24-27, 2026

Wednesday, June 24

TIME

6:00pm -7:30pm

TITLE

Faculty Dinner

Thursday, June 25 | Day 1 — Obesity

TIME

7:00am-8:00am

TITLE

 Breakfast & Registration

Session 1: Obesity

Moderators: Carel Le Roux and Ildiko Lingvay

TIME

8:00am-8:10am

TITLE

Opening Remarks of the SOLAR Conference 

PRESENTER

PRESENTER

Mazen Noureddin, MD, MHSc

TIME

8:10am-8:30am


TITLE

State of the Art Lecture: The Evolving Understanding of the Disease of Obesity that is Impacting Clinical Trials

PRESENTER

PRESENTER

Carel Le Roux MD, PhD

TIME

8:30am-8:45am

TITLE

Panel discussion

TIME

8:45am-9:05am


TITLE

What did we learn with the STEP and SELECT trials with Semaglutide that changed how we want to do clinical trials now?

PRESENTER

PRESENTER

Dominica Rubino, MD

TIME

9:05am-9:20am

TITLE

Panel discussion

TIME

9:20am-9:40am

TITLE

What did we learn with the SURMOUNT trials with Tirzepatide that changed how we do clinical trials now?

PRESENTER

PRESENTER

Layla AboShamat, MD

TIME

9:40am-9:55am

TITLE

Discussion

PRESENTER

PRESENTER

Carel Le Roux, Dominica Rubino, Layla AboShamat, Ildiko Lingvay, Julia Dunn, Abd Tahrani

TIME

9:55am-10:10am

TITLE

Break

TIME

10:10am-10:35am

TITLE

What did we learn with the new phase 2 and 3 trials with Multihormone Agonists that changed how we want to do clinical trials now?

PRESENTER

PRESENTER

Ildiko Lingvay, MD

TIME

10:35am-11:00am


TITLE

Panel discussion

PRESENTER

PRESENTER

Carel Le Roux, Dominica Rubino,  Ildiko Lingvay, Dimple Desai, Julia Dunn, Isabel Kloer, Abd Tahrani, Georgios Dimitriadis

TIME

11:00am-12:00pm

TITLE

Ipsen Pharmaceuticals Product Theater (Lunch) 

Session 2: Cholestatic Liver Disease / Genetic Liver Disease / and Hepatitis B

Moderators: Raj Vuppalanchi and Lily Dara 

TIME

12:00pm-12:20pm

TITLE

PBC Update: Current Status and Future Directions 

PRESENTER

PRESENTER

Raj Vuppalanchi, MD

TIME

12:20pm-12:40pm

TITLE

PSC/AIH/Other Autoimmune Liver Diseases: Novel Agents and Promising Trials

PRESENTER

PRESENTER

Lily Dara 

TIME

12:40pm-1:00pm

TITLE

Genetic Liver Diseases 1: What's New in A1AT Deficiency, Wilson Disease, and Hemochromatosis

PRESENTER

PRESENTER

Kris Kowdley, MD

TIME

1:00pm-1:20pm

TITLE

Genetic Liver Disease 2: Genetic Cholestasis from PFIC to Alagille Syndrome to BASD

PRESENTER

PRESENTER

Wing-Kin Syn, MD

TIME

1:20pm-1:40pm

TITLE

Discussion and Q&A

PRESENTER

PRESENTER

Panel: Raj Vuppalanchi, Lily Dara, Kris Kowdley

Moderators: Norah Terrault 

TIME

1:40pm-2:00pm

TITLE

Practice Guidelines and Trials Challenges for Chronic HBV and HDV: Are We Moving the Needle?

PRESENTER

PRESENTER

Theo Heller

TIME

2:00pm-2:20pm

TITLE

Update on Clinical Trials of Novel Agents Targeting Functional Cure for HBV

PRESENTER

PRESENTER

Norah Terrault, MD

TIME

2:20pm-2:40pm

TITLE

CHB Treatment and HCV Elimination in 2030: Can we Predict the Future?

PRESENTER

PRESENTER

Elizabeth C. Verna, MD

TIME

2:40pm-3:00pm

TITLE

Discussion and Q&A

PRESENTER

PRESENTER

Panel: Norah Terrault

TIME

3:00pm-3:20pm

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

3:20pm -6:00pm

TITLE

Meetings, Poster Viewing, and Self-Directed Learning

TIME

6:00pm-7:00pm

TITLE

Reception

Friday, June 26  | Day 2 — MASH


TIME

8:30am - 9:15am

TITLE

Gilead Product Theater (Breakfast) 

Session 3: Clinical & Research Implications in MASH

Moderators: Naim Alkhouri 

TIME

9:15am-9:40am

TITLE

The Stephen Harrison State of Art Lecture: MASH in 2026

PRESENTER

PRESENTER

Mazen Noureddin, MD, MHSc

TIME

9:40am-10:00am

TITLE

Resmetirom and Semaglutide are now FDA Approved: What Should Clinicians Do Today?

PRESENTER

PRESENTER

Naim Alkhouri, MD

TIME

10:00am-10:20am

TITLE

Current Update on Phase 3 Trials

PRESENTER

PRESENTER

Rohit Loomba, MD

TIME

10:20am-10:35am

TITLE

Break

TIME

10:35am-10:55am

TITLE

RNA Interference and Genetic Therapies

PRESENTER

PRESENTER

Naga Chalasani, MD

TIME

10:55am-11:15am

TITLE

PROs in MASH Trials, Which One and How to Implement

PRESENTER

PRESENTER

Zobair Younossi, MD

TIME

11:15am -11:35am

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

11:35am-12:30pm

TITLE

Q&A and Panel Discussion 

PRESENTER

PRESENTER

Panel: Naim Alkhouri, Christophe Arbet-Engels, Becky Taub, Manu Chakravarthy, Rohit Loomba, Zobair Younossi, Mazen Noureddin & Meena Bansal

TIME

12:30pm-1:30pm

TITLE

Madrigal Pharmaceuticals Product Theater (Lunch) 

Session 4: NITs and Trials Design

Moderators: Mazen Noureddin and 

TIME

1:30pm-1:50pm

TITLE

NITs: The Reasonably Likely to Predict Outcomes and the path to full Validation

PRESENTER

PRESENTER

Jorn Schattenberg, MD

TIME

1:50pm-2:10pm

TITLE

Update on the Role of liver biopsy in MASH trials: When do I use it?

PRESENTER

PRESENTER

Cynthia Behling, MD

TIME

2:10pm-2:30pm

TITLE

Designing Non-Cirrhotic MASH Trials without Liver Biopsy: Pros & Cons

PRESENTER

PRESENTER

Maru Rinella, MD

TIME

2:30pm-2:50pm

TITLE

Designing Cirrhosis Trials

PRESENTER

PRESENTER

Arun Sanyal, MD

TIME

2:50pm-3:10pm

TITLE

Panel and Q&A

PRESENTER

PRESENTER

Panel: Mazen Noureddin, Stuart Kendrick, Jorn Schattenberg, Cynthia Behling, Maru Rinella, Michael Charlton

TIME

3:10pm-3:30pm

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

Saturday, June 27 | Day 3 — MASH, MetALD and ALD

TIME

7:00am-8:00am

TITLE

Breakfast & CME or Product Theater 

Session 5: Dual Perspectives: Sponsors & Site Exchange

Moderators:

TIME

8:00am-8:20am

TITLE

Overcoming MASH Trials Difficulties, Liver Biopsy, Biomarkers and Retention

PRESENTER

PRESENTER

Rashmee Patil, MD

TIME

8:20am-8:40am

TITLE

Use of GLP-1 and their Effect in MASH Trials: How to control and mitigate during trials

PRESENTER

PRESENTER

Meena Bansal, MD

TIME

8:40am-9:00am

TITLE

What is a Stellar MASH Site: The Sponsor’s Wish List

PRESENTER

PRESENTER

Michelle Long, MD

TIME

9:00am-9:20am

TITLE

Panel and Q&A

PRESENTER

PRESENTER

Panel: Ramy Younes, Meena Bansal, Rashmee Patil, Michelle Long, Hank Mansbach, Jason Campagna

TIME

9:20am-9:30am

TITLE

Break

Session 6: Shark Tank: Innovative Biotech’s meet KOLs and Big Pharma (MASH)

Sharks: Mazen Noureddin, Naim Alkhouri, Bill Sillbold, Stuart Kendrick 

TIME

9:30am-9:45am

TITLE

Company 1  (Kryia)

TIME

9:45am-9:55am

TITLE

Sharks

TIME

9:55am-10:10am

TITLE

Company 2 (HepaNova)

TIME

10:10am-10:20am

TITLE

Sharks

TIME

10:20am-10:35am

TITLE

Company 3 (Opko)

TIME

10:35am-10:45am

TITLE

Sharks

TIME

10:45am-11:15am

TITLE

Q&A

TIME

11:15am-12:15pm

TITLE

Boehringer Ingelheim Pharmaceuticals Product Theater (Lunch)

Session 7: The Future of MetALD and ALD

Moderators: Mazen Noureddin

TIME

12:15pm-12:35pm

TITLE

Current Update on Clinical Trials for MetALD and ALD

PRESENTER

PRESENTER

Naim Alkhouri, MD

TIME

12:35pm-12:55pm

TITLE

MetALD and ALD Phase 2 Trials Design

PRESENTER

PRESENTER

Brian Lee, MD

TIME

12:55pm-1:15pm

TITLE

MetALD and ALD Phase 3 Trials Design

PRESENTER

PRESENTER

Mazen Noureddin, MD

TIME

1:15pm-1:30pm

TITLE

Q&A

Session 8: Dual Perspectives: Sponsors & Sites Exchange

Moderators: Gene Im & Belle Vivica Van Rosmalen

TIME

1:30pm-1:45pm

TITLE

How to Deal with Active Alcohol Intake during the trials

PRESENTER

PRESENTER

Jessica Mellinger, MD 

TIME

1:45pm-2:00pm

TITLE

NIT in MetALD/ALD: The Reasonably Likely to Predict Outcomes

PRESENTER

PRESENTER

Gene Im

TIME

2:00pm-2:20pm

TITLE

Sites Challenges in MetALD and ALD trials (Sites vs Sponsors Perspective (10 min each)

PRESENTER

PRESENTER

Nikhil Vergis, MD (sponsor) & Manal Abdelmalek, MD (Site)

TIME

2:20pm-2:40pm

TITLE

Panel and Q&A

PRESENTER

PRESENTER

Panel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Belle Vivica van Rosmalen, Maja Thiele

TIME

2:40pm – 2:50pm

TITLE

CDs Abstract of Choice – 1 Oral @10 mins

TIME

2:50pm-3:00pm

TITLE

Break

Session 9: Shark Tank: Innovative Biotechs meet KOLs and Big Pharma (ALD/MetALD)

Sharks: Jane Hsiao, Mazen Noureddin, Juan Pablo Arab, Nikhil Vergis and Brian Lee 

TIME

3:00pm-3:10pm

TITLE

Company 1 (Gyre)

TIME

3:10pm-3:20pm

TITLE

Sharks

TIME

3:20pm-3:40pm

TITLE

Company 2 (Altimmune)

TIME

3:40pm-3:50pm

TITLE

Sharks

TIME

4:00pm-4:15pm

TITLE

Closing Remarks

PRESENTER

PRESENTER

Mazen Noureddin, MD & Naim Alkhouri, MD

Connecting liver, obesity, and metabolic science to improve patient care.

This conference looks at the bigger picture—how liver disease, obesity, and metabolic dysfunction intertwine. It creates a space where clinicians, researchers, and industry experts can break silos, share insights, and shape the future of care together. By weaving cutting-edge science with real-world clinical strategies, it challenges participants to rethink how breakthroughs move from the lab to the patient.